---
title: "Bayer's India unit posts quarterly profit rise as expenses shrink"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294984807.md"
description: "Bayer CropScience, the Indian unit of Bayer AG, reported a 15.4% increase in first-quarter profit to 3.22 billion rupees ($33.85 million) for the period ending June 30. This growth was driven by a 4.8% reduction in expenses, aided by an inventory-related gain, despite weaker demand caused by a poor monsoon start."
datetime: "2026-08-05T14:53:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294984807.md)
  - [en](https://longbridge.com/en/news/294984807.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294984807.md)
generator: "portal-rs"
---

# Bayer's India unit posts quarterly profit rise as expenses shrink

Aug 5 (Reuters) - Bayer CropScience posted a 15.4% rise in first-quarter profit on Wednesday on lower expenses, even as a weak start to the monsoon weighed on demand. The company, the Indian unit of Germany-based drugs and pesticides maker Bayer AG, posted a profit of 3.22 billion rupees ($33.85 million) for the quarter ended June 30. • Expenses fell 4.8%, helped by an inventory-related gain of

### Related Stocks

- [BAYRY.US](https://longbridge.com/en/quote/BAYRY.US.md)
- [BAYN.DE](https://longbridge.com/en/quote/BAYN.DE.md)
- [BAYZF.US](https://longbridge.com/en/quote/BAYZF.US.md)

## Related News & Research

- [Bayer says Japan approves sevabertinib for HER2-mutant NSCLC](https://longbridge.com/en/news/296745277.md)
- [MustGrow Receives First Milestone Payment from Bayer AG | MGROF Stock News](https://longbridge.com/en/news/296609006.md)
- [BAYN: Q2 2026 delivered solid sales and EBITDA growth, but free cash flow was impacted by litigation](https://longbridge.com/en/news/294773093.md)
- [BAYN: Strong 2025 results, innovation focus, and €2bn cost savings drive improved financial outlook](https://longbridge.com/en/news/294831947.md)
- [Bayer Swings to Net Profit on Smaller Litigation Charges](https://longbridge.com/en/news/294778020.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**